

Electronic Acknowledgement Receipt

EFS ID:	6964663
Application Number:	10531560
International Application Number:	
Confirmation Number:	3534
Title of Invention:	TREATMENT OF OSTEOARTHRITIS
First Named Inventor/Applicant Name:	Ian Alexander Shiels
Customer Number:	27683
Filer:	Mark D. Moore/Marty Miles
Filer Authorized By:	Mark D. Moore
Attorney Docket Number:	36672.6
Receipt Date:	05-FEB-2010
Filing Date:	27-JAN-2006
Time Stamp:	23:18:46
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$810
RAM confirmation Number	13021
Deposit Account	081394
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part/.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	36672_6_RCE.pdf	769798 783e0fd5f1cd72a3af3f57ecc200909fc48ff	no	3

Warnings:**Information:**

2	Amendment Submitted/Entered with Filing of CPA/RCE	36672_RCE_Accompany.pdf	2320837 2030ba7a7b4b959802947a6c5eb493fa7f44 42199	no	58
---	--	-------------------------	--	----	----

Warnings:**Information:**

3	NPL Documents	NPL_Anaya_Pulmonary_Involvement.PDF	229704 1712c331e2480d28eb2d327470b7193 cc39c	no	1
---	---------------	-------------------------------------	--	----	---

Warnings:**Information:**

4	NPL Documents	NPL_Arumugam_A_Small_Molecule_C5a.PDF	1962457 cadf2817068960de53c95c5ef8c77b1a8 03308	no	9
---	---------------	---------------------------------------	---	----	---

Warnings:**Information:**

5	NPL Documents	NPL_Arumugam_Protective_Effects.PDF	18464996 1cfdf2f9e80aa7175d5998c41a59c7d38 0de7	no	8
---	---------------	-------------------------------------	---	----	---

Warnings:**Information:**

6	NPL Documents	NPL_Baskaran_Dynamics_of_Tissue.PDF	2100933 05795fb47165a3b301d45e6bbcc23a7819 29452	no	9
---	---------------	-------------------------------------	--	----	---

Warnings:**Information:**

7	NPL Documents	NPL_Beam.pdf	2094646 1d2b85ec2adda3aee7e797875f731250 1776	no	12
---	---------------	--------------	---	----	----

Warnings:**Information:**

8	NPL Documents	NPL_Benoitton_Studies_On_Sensitivity.PDF	1576276 ca94ce081ed444998d61653bf152f 3734	no	8
---	---------------	--	--	----	---

Warnings:**Information:**

9	NPL Documents	NPL_Bernadelli_etal_Trends_and_Perspectives.PDF	4230050 5e56530bb5de96ec0f8ca2a2c2b95fb1a44976	no	21
---	---------------	---	---	----	----

Warnings:**Information:**

10	NPL Documents	NPL_Bertrand_CCR3_Blockade.PDF	2027274 d49813766cdcc0f535d90edec39a7fc07fb4ed	no	10
----	---------------	--------------------------------	---	----	----

Warnings:**Information:**

11	NPL Documents	NPL_Bodansky_Introduction_of_Amine.PDF	2860861 a5ef59d2c782cb52a3bc25d084a7a613e872a7	no	19
----	---------------	--	---	----	----

Warnings:**Information:**

12	NPL Documents	NPL_Brady_Large_Scale.PDF	1851584 c7213d4e74f685d114681556dc7c5d1b6f7c	no	6
----	---------------	---------------------------	---	----	---

Warnings:**Information:**

13	NPL Documents	NPL_Cain_Modulation_of_LigandSelectivity.PDF	1622694 d303798374ac49969aafe20b5b81362d515d4286f	no	9
----	---------------	--	--	----	---

Warnings:**Information:**

14	NPL Documents	NPL_Chan_Basic_Procedures.PDF	4445833 401114ce959af4648591917668153c160f5015	no	19
----	---------------	-------------------------------	---	----	----

Warnings:**Information:**

15	NPL Documents	NPL_Cheng_Trends_Perspectives_1995.PDF	3102513 4f6f4c48a5a975a992bcb4b4b93a95b5d41	no	18
----	---------------	--	--	----	----

Warnings:**Information:**

16	NPL Documents	NPL_Dinarello.pdf	329251 7c340bc1ca5a504b2b0ce9b23ee4b99edfa3dd	no	5
----	---------------	-------------------	--	----	---

Warnings:**Information:**

17	NPL Documents	NPL_Diop.pdf	1929873 42a7ab110f17171d6f6914bf53282b2d4b978	no	10
----	---------------	--------------	--	----	----

Warnings:**Information:**

18	NPL Documents	NPL_Fields_Solid_Phase.PDF	7371926 d:8ffad3ff2fb7536c78e09575c42d7ad15d 1189	no	28
----	---------------	----------------------------	---	----	----

Warnings:**Information:**

19	NPL Documents	NPL_Fukunaga_A_Novel.PDF	1840654 38803de0446d10cde3fc3fa3c0116e05c1 6a8f	no	9
----	---------------	--------------------------	---	----	---

Warnings:**Information:**

20	NPL Documents	NPL_Galatis_Trends_and_Perspectives.PDF	3732280 2fe083405384f2f2ed5b14402ef12b988f1c 389c	no	22
----	---------------	---	---	----	----

Warnings:**Information:**

21	NPL Documents	NPL_Gao_RecentAdvances.PDF	586436 3414918c0296a3c480672a1573327a716 bb1a6	no	14
----	---------------	----------------------------	--	----	----

Warnings:**Information:**

22	NPL Documents	NPL_Gaudilliere_Trends_Perspectives_2001.PDF	4539770 2e98118c1c907ad2d400256f8ea2971c -0xid	no	26
----	---------------	--	--	----	----

Warnings:**Information:**

23	NPL Documents	NPL_Gaudilliere_Trends_Perspectives_2000.PDF	4293100 270681901ad2c34f0c0a2b69853c9481f -0xidb	no	26
----	---------------	--	--	----	----

Warnings:**Information:**

24	NPL Documents	NPL_Harkin.pdf	1925050 0da60b04316ccac92ad641b274e28117db -1610a6	no	11
----	---------------	----------------	--	----	----

Warnings:**Information:**

25	NPL Documents	NPL_Haynes_Inhibition.PDF	980028 549801d8257216958d1044ec680861c -699ec	no	5
----	---------------	---------------------------	---	----	---

Warnings:**Information:**

26	NPL Documents	NPL_Heller.pdf	2363092 37a296c78ee20193bb8f7cdcc3007f5c -358	no	10
----	---------------	----------------	---	----	----

Warnings:**Information:**

27	NPL Documents	NPL_Ikeda_Simvastatin_Attenuates.PDF	1277713 2b66eeb15e34b234d86d3e6447feacfe60 66990	no	7
----	---------------	--------------------------------------	--	----	---

Warnings:**Information:**

28	NPL Documents	NPL_Johnson_Heterotrimeric.PDF	2707250 0f8a8fb1b947d991fdec29e91e516d471ecf fa29	no	11
----	---------------	--------------------------------	---	----	----

Warnings:**Information:**

29	NPL Documents	NPL_Makrides_Therapeutic_Inhibition.PDF	7370618 1eb7eb47a1f664b6f0251e2e10cc59513 28502	no	29
----	---------------	---	---	----	----

Warnings:**Information:**

30	NPL Documents	NPL_Morikis.pdf	2089339 e47d6782c1005417d8f6e844ce41f2b2ef 698d	no	11
----	---------------	-----------------	---	----	----

Warnings:**Information:**

31	NPL Documents	NPL_Morris_Hapten_Induces.PDF	2801940 b725ecade673051a931a981e0f2055b6c 1739	no	9
----	---------------	-------------------------------	--	----	---

Warnings:**Information:**

32	NPL Documents	NPL_Owen_Chemokine_Receptors.PDF	2214247 5e81af5e6207b4699044446f6f34b25f 1de1	no	10
----	---------------	----------------------------------	---	----	----

Warnings:**Information:**

33	NPL Documents	NPL_Paczkowski_pharmacological_Characterization.PDF	1468864 108026a60a07f015a31ca745ff167b5d3 5007	no	6
----	---------------	---	--	----	---

Warnings:**Information:**

34	NPL Documents	NPL_Piccolo_Chemotactic_Mediator.PDF	1303087 99e04d9a775b21b7a2205fe57192759434 724ea	no	7
----	---------------	--------------------------------------	--	----	---

Warnings:**Information:**

35	NPL Documents	NPL_Reid.pdf	237719 bf7de62e4b37436205f15614e6f30e6540 2bc51	no	2
----	---------------	--------------	---	----	---

Warnings:**Information:**

36	NPL Documents	NPL_Roschmann_Pulmonary_Fibrosis.PDF	206322 843a1c2f66466b6c96fb3998b3ed52718ef Seba	no	1
----	---------------	--------------------------------------	---	----	---

Warnings:**Information:**

37	NPL Documents	NPL_Schmid.Requirement_for.PDF	1365219 2512001e8fb6fb7ec13c445d0156c694 e5d44	no	6
----	---------------	--------------------------------	--	----	---

Warnings:**Information:**

38	NPL Documents	NPL_Schuda_A_Short.PDF	935232 99f0f52ae33f27ed84d19f1f1ebf293539 d98	no	3
----	---------------	------------------------	---	----	---

Warnings:**Information:**

39	NPL Documents	NPL_Short_Effects_of.PDF	818646 a8fb78e6808aae4b2db7771f91b69c4984 9798	no	4
----	---------------	--------------------------	--	----	---

Warnings:**Information:**

40	NPL Documents	NPL_Smith_Organic_Synthesis.PDF	598081 5ef8fe42626589112374ae228415c82e0ff b6005	no	5
----	---------------	---------------------------------	--	----	---

Warnings:**Information:**

41	NPL Documents	NPL_Steinauer_Studies_on.PDF	857561 82705148ddc26e4446a959b791581e eeef4	no	4
----	---------------	------------------------------	---	----	---

Warnings:**Information:**

42	NPL Documents	NPL_Stewart_Current_Therapy.PDF	1122137 4a3c94ca560d6ad1e76c74d7d76294c23 2412a	no	5
----	---------------	---------------------------------	---	----	---

Warnings:**Information:**

43	NPL Documents	NPL_Strachan_Inhibition_of.PDF	1915686 2be66d4a24b98bfaf0f7053ecc645d318ef 5022	no	9
----	---------------	--------------------------------	--	----	---

Warnings:**Information:**

44	NPL Documents	NPL_Striter_Effects_of.PDF	490293 e29813cfdf124297bf9f956913e1335ff014 1d5e	no	2
----	---------------	----------------------------	--	----	---

Warnings:**Information:**

45	NPL Documents	NPL_Szebeni.pdf	2134014 b009a6dc7d8fb64c1aefca0200e48b4b e2df	no	9
----	---------------	-----------------	---	----	---

Warnings:**Information:**

46	NPL Documents	NPL_Taylor_Regulations_of_th e.PDF	1974301 e2691bf5e1ca298dbb02e96a0ff0ff3096f7d74 e27	no	10
----	---------------	---------------------------------------	---	----	----

Warnings:**Information:**

47	NPL Documents	NPL_Toulouse.pdf	1622761 5ab5a9ca9ebc246019d1aeef125c05954643 beed	no	7
----	---------------	------------------	---	----	---

Warnings:**Information:**

48	NPL Documents	NPL_VanaAssche_Emerging_D rugs.PDF	2369716 Sec2f9678efc2ff82ff903367e02126ef033716 9a6d	no	11
----	---------------	---------------------------------------	--	----	----

Warnings:**Information:**

49	NPL Documents	NPL_Wong_Small_Molecular. PDF	2179937 528be8725247584b4d99e6bf581610759 1a65	no	9
----	---------------	----------------------------------	--	----	---

Warnings:**Information:**

50	NPL Documents	NPL_Woodruff_Species_Depend ence.PDF	1107265 0e49b49c2159176175a91689187710294 e667	no	7
----	---------------	---	--	----	---

Warnings:**Information:**

51	NPL Documents	NPL_Mita.pdf	2129518 36e69b05f27ec169fa2e9f38a1c9c5efc7a 669	no	10
----	---------------	--------------	---	----	----

Warnings:**Information:**

52	NPL Documents	NPL_Piccolo_Role_of.PDF	2825893 bc9991a7a6f9210ab4e0224811c5d00469 60418	no	15
----	---------------	-------------------------	--	----	----

Warnings:**Information:**

53	Information Disclosure Statement (IDS) Filed (SB/08)	36672_6_IDS1.pdf	1102098 0086a6b7e72fc6d8056da070e91ab1d2 beef1e	no	8
----	---	------------------	---	----	---

Warnings:**Information:**

A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.

54	Fee Worksheet (PTO-875)	fee-info.pdf	30002 b7A/b7B/b7f/b6/b6B/b6C/b2/b3(b)(6)(b)(7)(D)(7)(E)(7)(F)(7)(G)	no	2
----	-------------------------	--------------	--	----	---

Warnings:

Information:

Total Files Size (in bytes):

110207375

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.